Bio-Techne (TECH) Profit After Tax (2009 - 2026)
Bio-Techne (TECH) posted quarterly Profit After Tax of $51.0 million for Q1 2026, up 94.94% year-over-year from $26.2 million in Q1 2025, and up 27.43% quarter-over-quarter from $40.1 million in Q4 2025.
Analysis
Bio-Techne (TECH) Profit After Tax (2009 - 2026) Analysis & Trends
Bio-Techne's Profit After Tax history runs 18 years deep, the most recent figure standing at $51.0 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 94.94% year-over-year to $51.0 million; the TTM figure through Mar 2026 stood at $110.8 million (up 13.74% YoY), while the FY2025 annual figure was $73.4 million, down 52.9% from the prior year.
- Profit After Tax for Q1 2026 stood at $51.0 million, up from $40.1 million in the prior quarter.
- The five-year high for Profit After Tax was $89.7 million in Q3 2022, with the low at -$219.1 million in Q2 2022.
- The 5-year median for Profit After Tax is $41.8 million (2023), against an average of $28.1 million.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax slumped 1102.75% in 2022, then surged 329.51% in 2025.
- Bio-Techne's Profit After Tax stood at $50.0 million in 2022, then decreased by 16.37% to $41.8 million in 2023, then sank by 77.7% to $9.3 million in 2024, then surged by 329.51% to $40.1 million in 2025, then gained by 27.43% to $51.0 million in 2026.
- Business Quant data shows TECH's Profit After Tax at $51.0 million in Q1 2026, $40.1 million in Q4 2025, and $33.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Bio-Techne | 11.30 Bn | 11.03 Bn | 211.39 Mn | 54.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.62 Mn |
| Mar 31, 2026 | 51.05 Mn |
| Dec 31, 2025 | 40.06 Mn |
| Sep 30, 2025 | 38.19 Mn |
| Jun 30, 2025 | 758,000.00 |
| Mar 31, 2025 | 26.19 Mn |
| Dec 31, 2024 | 34.89 Mn |
| Sep 30, 2024 | 51.83 Mn |
| Jun 30, 2024 | 40.59 Mn |
| Mar 31, 2024 | 49.06 Mn |
| Dec 31, 2023 | 41.82 Mn |
| Sep 30, 2023 | 50.99 Mn |
| Jun 30, 2023 | 82.97 Mn |
| Mar 31, 2023 | 71.79 Mn |
| Dec 31, 2022 | 50.01 Mn |
| Sep 30, 2022 | 89.73 Mn |
| Jun 30, 2022 | 59.38 Mn |
| Mar 31, 2022 | 65.07 Mn |
| Dec 31, 2021 | 72.06 Mn |
| Sep 30, 2021 | 68.98 Mn |